Can The Gains Continue For Adverum Biosciences After An 18% Move In 5 Days?
- Friday, January 22, 2021, 8:07
- Market
- Add a comment
Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in regulatory filings that CEO Laurent Fischer and Chairman Patrick Machado together bought close to…
About the Author
admin123 has written 23544 stories on this site.
